Wavefront-guided laser in situ keratomileusis with the Alcon CustomCornea and the VISX CustomVue: Three-month results

Shady T. Awwad, Mohamed El-Kateb, Robert W Bowman, Harrison D Cavanagh, James P McCulley

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

PURPOSE: To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems. METHODS: Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean sphere of -3.90 ± 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 ± 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 ± 1.54 D. The CustomVue group had a sphere of -3.87 ± 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 ± 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 ± 1.46 D. At 3 months, 98% of the CustomCornea group and 95% of the CustomVue group were within ±0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group. CONCLUSION: Wavefront-guided LASIK with both systems is safe and effective.

Original languageEnglish (US)
JournalJournal of Refractive Surgery
Volume20
Issue number5
StatePublished - Sep 2004

Fingerprint

Laser In Situ Keratomileusis
Visual Acuity
Contrast Sensitivity
Diabetic Retinopathy
Coma
Lasers
Outcome Assessment (Health Care)
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{33a0e3ba8d294eecb5790845611c5ca6,
title = "Wavefront-guided laser in situ keratomileusis with the Alcon CustomCornea and the VISX CustomVue: Three-month results",
abstract = "PURPOSE: To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems. METHODS: Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean sphere of -3.90 ± 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 ± 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 ± 1.54 D. The CustomVue group had a sphere of -3.87 ± 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 ± 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 ± 1.46 D. At 3 months, 98{\%} of the CustomCornea group and 95{\%} of the CustomVue group were within ±0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group. CONCLUSION: Wavefront-guided LASIK with both systems is safe and effective.",
author = "Awwad, {Shady T.} and Mohamed El-Kateb and Bowman, {Robert W} and Cavanagh, {Harrison D} and McCulley, {James P}",
year = "2004",
month = "9",
language = "English (US)",
volume = "20",
journal = "Journal of Refractive Surgery",
issn = "0883-0444",
publisher = "Slack Incorporated",
number = "5",

}

TY - JOUR

T1 - Wavefront-guided laser in situ keratomileusis with the Alcon CustomCornea and the VISX CustomVue

T2 - Three-month results

AU - Awwad, Shady T.

AU - El-Kateb, Mohamed

AU - Bowman, Robert W

AU - Cavanagh, Harrison D

AU - McCulley, James P

PY - 2004/9

Y1 - 2004/9

N2 - PURPOSE: To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems. METHODS: Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean sphere of -3.90 ± 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 ± 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 ± 1.54 D. The CustomVue group had a sphere of -3.87 ± 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 ± 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 ± 1.46 D. At 3 months, 98% of the CustomCornea group and 95% of the CustomVue group were within ±0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group. CONCLUSION: Wavefront-guided LASIK with both systems is safe and effective.

AB - PURPOSE: To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems. METHODS: Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean sphere of -3.90 ± 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 ± 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 ± 1.54 D. The CustomVue group had a sphere of -3.87 ± 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 ± 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 ± 1.46 D. At 3 months, 98% of the CustomCornea group and 95% of the CustomVue group were within ±0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group. CONCLUSION: Wavefront-guided LASIK with both systems is safe and effective.

UR - http://www.scopus.com/inward/record.url?scp=4644317870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644317870&partnerID=8YFLogxK

M3 - Article

C2 - 15523984

AN - SCOPUS:4644317870

VL - 20

JO - Journal of Refractive Surgery

JF - Journal of Refractive Surgery

SN - 0883-0444

IS - 5

ER -